Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation
Tali Lang(Cabrini Hospital), James Harris(Monash Health), Nadia S. Deen(Monash Health), Ashley Mansell(Monash University), Eric F. Morand(Novartis (Switzerland)), Ivo Müeller(The University of Melbourne), Matthew C. J. Wilce(Discovery Institute), Jacinta P. W. Lee(Monash Health), Francesca Baiwog(Papua New Guinea Institute of Medical Research), Elizabeth H. Aitken(The University of Melbourne), Colin E. Skene(The University of Melbourne), Danielle I. Stanisic(Griffith University), Michelle D. Tate(Hudson Institute), Daouda A. K. Traoré(Australian Regenerative Medicine Institute), Sarah J. Creed(Hudson Institute of Medical Research), Kirstin Elgass(Hudson Institute of Medical Research), Anita A. Pinar(Monash University), Huapeng Fan(Monash Medical Centre)
Cited by 190
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726